Literature DB >> 19623166

Definition of Barrett's esophagus: time for a rethink--is intestinal metaplasia dead?

Robert H Riddell1, Robert D Odze.   

Abstract

The definition of Barrett's esophagus (BE) varies worldwide, particularly with regard to the need to identify goblet cells in esophageal biopsies in order to diagnose this condition. Problems related to the need to identify goblet cells to diagnose BE include the facts that goblet cells are uncommon in pediatric patients with BE, a small percentage of adults with columnar metaplasia of the esophagus do not contain goblet cells, the chances of detecting goblet cells are proportional to the length of columnar metaplasia, sampling error is common, and interpretation and differentiation of goblet cells vs. pseudogoblet cells may be difficult in some circumstances. In addition, goblet cells have been shown to wax and wane over the natural history of BE. Recent studies suggest that the background nongoblet epithelium in BE is biologically intestinalized, and shows a variety of molecular abnormalities similar to the goblet cell-containing epithelium. In addition, several retrospective and outcome studies suggest a well-defined risk of neoplasia in patients with esophageal columnar metaplasia, but without goblet cells. There are important clinical and economic implications to these findings and also with regard to the definition of BE. This review provides evidence to suggest that a diagnosis of BE should not require demonstration of goblet cells in mucosal biopsies, and offers considerable data to support the notion that a nongoblet epithelium is also at risk of malignancy. Guidelines for the diagnosis of BE need to consider revisions that take into account new data regarding nongoblet cell epithelium in BE, and the difficulties in recognizing columnar metaplasia that measures less than 1 cm in length.

Entities:  

Mesh:

Year:  2009        PMID: 19623166     DOI: 10.1038/ajg.2009.390

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  44 in total

1.  Math1/Atoh1 contributes to intestinalization of esophageal keratinocytes by inducing the expression of Muc2 and Keratin-20.

Authors:  Jianping Kong; Mary Ann S Crissey; Antonia R Sepulveda; John P Lynch
Journal:  Dig Dis Sci       Date:  2011-12-07       Impact factor: 3.199

2.  Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia.

Authors:  Michael Quante; Govind Bhagat; Julian A Abrams; Frederic Marache; Pamela Good; Michele D Lee; Yoomi Lee; Richard Friedman; Samuel Asfaha; Zinaida Dubeykovskaya; Umar Mahmood; Jose-Luiz Figueiredo; Jan Kitajewski; Carrie Shawber; Charles J Lightdale; Anil K Rustgi; Timothy C Wang
Journal:  Cancer Cell       Date:  2012-01-17       Impact factor: 31.743

Review 3.  [Barrett's esophagus. An update].

Authors:  G B Baretton; D E Aust
Journal:  Pathologe       Date:  2012-02       Impact factor: 1.011

Review 4.  Barrett's esophagus: Clinical issues.

Authors:  Stuart Jon Spechler
Journal:  Gastrointest Endosc Clin N Am       Date:  2011-01

Review 5.  Cdx genes, inflammation, and the pathogenesis of intestinal metaplasia.

Authors:  Douglas B Stairs; Jianping Kong; John P Lynch
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

6.  Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process.

Authors:  Cathy Bennett; Nimish Vakil; Jacques Bergman; Rebecca Harrison; Robert Odze; Michael Vieth; Scott Sanders; Laura Gay; Oliver Pech; Gaius Longcroft-Wheaton; Yvonne Romero; John Inadomi; Jan Tack; Douglas A Corley; Hendrik Manner; Susi Green; David Al Dulaimi; Haythem Ali; Bill Allum; Mark Anderson; Howard Curtis; Gary Falk; M Brian Fennerty; Grant Fullarton; Kausilia Krishnadath; Stephen J Meltzer; David Armstrong; Robert Ganz; Gianpaolo Cengia; James J Going; John Goldblum; Charles Gordon; Heike Grabsch; Chris Haigh; Michio Hongo; David Johnston; Ricky Forbes-Young; Elaine Kay; Philip Kaye; Toni Lerut; Laurence B Lovat; Lars Lundell; Philip Mairs; Tadakuza Shimoda; Stuart Spechler; Stephen Sontag; Peter Malfertheiner; Iain Murray; Manoj Nanji; David Poller; Krish Ragunath; Jaroslaw Regula; Renzo Cestari; Neil Shepherd; Rajvinder Singh; Hubert J Stein; Nicholas J Talley; Jean-Paul Galmiche; Tony C K Tham; Peter Watson; Lisa Yerian; Massimo Rugge; Thomas W Rice; John Hart; Stuart Gittens; David Hewin; Juergen Hochberger; Peter Kahrilas; Sean Preston; Richard Sampliner; Prateek Sharma; Robert Stuart; Kenneth Wang; Irving Waxman; Chris Abley; Duncan Loft; Ian Penman; Nicholas J Shaheen; Amitabh Chak; Gareth Davies; Lorna Dunn; Yngve Falck-Ytter; John Decaestecker; Pradeep Bhandari; Christian Ell; S Michael Griffin; Stephen Attwood; Hugh Barr; John Allen; Mark K Ferguson; Paul Moayyedi; Janusz A Z Jankowski
Journal:  Gastroenterology       Date:  2012-04-24       Impact factor: 22.682

7.  Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study.

Authors:  Shivaram Bhat; Helen G Coleman; Fouad Yousef; Brian T Johnston; Damian T McManus; Anna T Gavin; Liam J Murray
Journal:  J Natl Cancer Inst       Date:  2011-06-16       Impact factor: 13.506

Review 8.  Barrett esophagus: what a mouse model can teach us about human disease.

Authors:  Michael Quante; Julian A Abrams; Yoomi Lee; Timothy C Wang
Journal:  Cell Cycle       Date:  2012-10-24       Impact factor: 4.534

Review 9.  History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus.

Authors:  Stuart Jon Spechler; Rebecca C Fitzgerald; Ganapathy A Prasad; Kenneth K Wang
Journal:  Gastroenterology       Date:  2010-01-18       Impact factor: 22.682

10.  Barrett's esophagus: is the goblet half empty?

Authors:  Stuart Jon Spechler
Journal:  Clin Gastroenterol Hepatol       Date:  2012-08-17       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.